I trained as a clinical neurologist before becoming a basic scientist. In my 34 years as a practicing scientist, I did research in immunology, cell biology, and developmental neurobiology before retiring in 2002 (Raff, 2006) . Despite 9 years of medical training, I chose to work exclusively on mice and rats and only rarely on the biology of disease.
If I were starting a research career today, however, I would follow a very different path. One reason is that I now have a 7-year-old grandson with autism, which has greatly stimulated my interest in autism spectrum disorders (ASDs) and other neuropsychiatric conditions. Another is that technological advances have made it possible to study the brain in ways that were unimaginable even a few years ago.
I would begin with mutations known to have an important role in some individuals with a major neuropsychiatric disease such as autism, schizophrenia, or bipolar disorder. Armed, for example, with a mutation that can cause or greatly increase the risk of bipolar disorder in some individuals, I could well be on a tractable pathway to understanding normal human mood control, which is dramatically disturbed in bipolar individuals and is still poorly understood.
There are other good reasons for studying neuropsychiatric disorders. These conditions are an enormous burden to society, in terms of both economic cost and human suffering: they are responsible for more than 40% of all years lived with disability in North America and Europe (Hyman, 2008) . They are still largely mysterious, which is mainly why there has been so little advance in their medical treatment in the past 60 years or so. Nonetheless, there are grounds for optimism. In most neurodegenerative diseases such as Alzheimer's and Parkinson's diseases and amyotrophic lateral sclerosis (ALS), nerve cells progressively degenerate and die, but, in the neuropsychiatric disorders, nerve cells generally do not degenerate or die. Moreover, recent studies of mouse models of genetic forms of neuropsychiatric disorders suggest that many of the behavioral and physiological abnormalities reflect reversible functional defects in the adult brain, rather than irreversible structural defects (Ehninger et al., 2008) . There is now a pressing need to discover what these functional neurobiological defects are.
Rapid advances in analyzing DNA in large numbers of affected individuals have made it possible to identify genetic contributions to some of the major neuropsychiatric disorders (Hyman, 2008) . The genetic contributions are mainly of two types: (1) common genetic variants (polymorphisms), each of which has a small effect, generally increasing the risk of developing the disorder less than 2-fold, and (2) rare mutations that have a large effect on risk and, in some cases, can be causative. As shown for a number of neurodegenerative diseases, even when a large-effect genetic abnormality occurs in only a small subset of individuals with the disease, it can allow the production of powerful animal models for analyzing the disease process. Animal models of Alzheimer's and Parkinson's diseases and ALS, for example, have revolutionized the study of these diseases, and they have depended on the initial identification of large-effect mutations in uncommon familial forms of the diseases (for example, Rosen et al., 1993 ).
An increasing number of large-effect mutations are now being identified in some of the major neuropsychiatric disorders, and there are excellent mouse models for a number of them. An especially informative example is Rett syndrome, in which the mutant gene is MECP2 on the X chromosome (Chahrour and Zoghbi, 2007) . The gene encodes a protein that binds to methylated cytosines in DNA and is thought to regulate the expression of many genes. Whereas boys with an MECP2 mutation die early, girls (who have one good copy of MECP2) develop normally for a year or two and then rapidly regress: they lose speech and develop cognitive and autonomic defects, ataxia, tremor, and irregular breathing; eventually, their condition stabilizes or even improves somewhat, and they usually live a normal life span. Many girls with Rett syndrome develop autistic features, in which case it is considered a "syndromic" form of ASD, as the autism is only part of a more complex neurological disorder. Mouse models of Rett syndrome closely resemble the human condition: whereas male mice develop neurological signs at 6 weeks and die at around 10 weeks, females develop normally for 5-10 months and then regress. The female mice develop similar neurological signs to those seen in girls with Rett syndrome, and like them, the female mice eventually stabilize and live a normal life span.
Many children with ASD also regress toward the end of their second year. The mechanism of regression in both Rett syndrome and other ASDs remains a mystery. Does it reflect a failure to maintain or strengthen some specific neuronal connections, for example? The Rett syndrome mouse seems an ideal model to find out.
New Routes into the Human Brain
The combination of human genetics, animal models, and induced pluripotent stem cells is likely to revolutionize our understanding of neuropsychiatric disorders, leading to new therapies and insights into how the normal human brain works. This is the territory I would explore if I were starting my research career today.
Adrian Bird and colleagues investigated a different question in Rett mice. They made a Rett mouse in which they could reverse the genetic defect in the adult animal (Guy et al., 2007) . They replaced the normal MECP2 gene with one containing an excisable stop signal, so the MeCP2 protein could not be made until the stop signal was excised. In the same mouse, they expressed an inducible transgene that encodes a DNA recombinase enzyme (Cre recombinase) that could be activated by the estrogen analog tamoxifen; the activated enzyme removes the stop signal, allowing the MeCP2 protein to be made. Remarkably, treatment of severely disabled adult mice with tamoxifen reversed most of the neurological and physiological deficits within a few weeks. As Rett syndrome has been considered a developmental brain disorder, this result was entirely unexpected. Subsequently, a number of other genetic mouse models of neuropsychiatric disorders have been partially reversed by drug treatment of adult mice (Ehninger et al., 2008) . These are very encouraging results, with promising implications for the treatment of these devastating disorders in humans. Interestingly, the first report of the partial reversal of a genetic brain disorder in a mouse model involved Huntington's disease, a classical neurodegenerative disorder in which a mutant form of the protein huntingtin accumulates in neurons. Turning off the mutant huntingtin transgene at 18 weeks in an inducible mouse model of the disease led to the disappearance of the mutant protein and a partial reversal of both the neuropathology and motor abnormalities (Yamamoto et al., 2000) . All brain functions depend on synaptic connections between nerve cells, and there is increasing evidence that defects in these connections may be responsible for some of the major neuropsychiatric disorders. Some large-effect mutations in genes that encode proteins that function only at synapses, for example, can predispose to ASDs (Jamain et al., 2003) . Many hundreds of different proteins operate at synapses, and it is possible that mutations and polymorphisms in a number of the genes that encode these proteins can increase the risk of ASDs. So far, none of the large-effect mutations found to predispose to ASDs are specific for ASDs; the same mutations can be associated with cognitive impairment, seizures, or other neuropsychiatric disorders (Abrahams and Geschwind, 2008) .
How can we test the possibility that a synaptic defect is responsible for a particular neuropsychiatric disorder in humans? A direct way would be to study synaptic behavior in the brains of affected individuals, but this cannot yet be done in the intact human brain. A possible alternative route involves the production of induced pluripotent stem (iPS) cells from adult cells derived from individuals with these disorders and then inducing these iPS cells to form neurons and synapses. It is this strategy that I would pursue if I were starting out in science today, but I would start with a mouse model and iPS cells derived from it, before turning to human iPS cells.
Thanks to the pioneering efforts of Shinya Yamanaka, it is now possible to produce iPS cells from mouse or human somatic cells by transiently expressing several transgenes that encode specific transcription factors (Yamanaka, 2009 ). Some of the transfected cells can be isolated as cell lines that closely resemble embryonic stem (ES) cells: they can proliferate indefinitely in culture and give rise to almost any cell type normally found in the body. They can form nerve cells, for example, which in turn can form synapses-either in culture or after transplantation into an embryonic mouse brain.
I would aim for a relatively simple model. One possibility would be to start with a gene that encodes a protein thought to operate exclusively at synapses and where mutations can have a major role in some individuals with an ASD. Neuroligin 4 (NLGN4), for example, encodes a postsynaptic cell adhesion protein (Sudhof, 2008) , and large-effect mutations in the gene have been found in a small number of ASD individuals (Jamain et al., 2003) , as well as in some individuals with cognitive impairment without an ASD (Laumonnier et al., 2004 ). An NLGN4-deficient mouse has highly selective defects in "social" interactions and vocalization, resembling some of the core defects in individuals with an ASD (Jamain et al., 2008) .
First, I would try to determine which parts of the brain and which cell types are responsible for the behavioral phenotype in the NLGN4-deficient mouse: I would either inactivate the NLGN4 gene in specific brain regions or specific cell types or try to rescue the phenotype of NLGN4-deficient mice by putting the wild-type NLGN4 gene back into specific brain regions or specific cell types. Once I had identified the relevant brain regions and cell types, I would take advantage of the powerful techniques for analyzing the mouse brain, either intact or in slices, to look in these regions for possible defects in synapse formation, maturation, function, plasticity, and homeostasis, as well as for defects in neural circuits. I would also try to reproduce any identified defects in dissociated cell cultures prepared from these regions. Crucially, to inform my eventual studies using human iPS cells, I would make iPS cells from the mutant mice and try to induce them to produce the appropriate types of cells and synaptic connections, either in culture or in mouse embryos, in an attempt to reproduce the identified abnormalities. The remarkable finding that mouse ES cells in culture can produce the multiple types of pyramidal neurons normally found in the mouse cerebral cortex and produce them in the normal developmental sequence (Gaspard et al., 2008) increases my confidence that this iPS cell strategy will work.
If I managed to achieve all of this, which could well take years, I would test candidate drugs to see if any could correct the defects in mutant brain slices or cultures. If none worked, I would try to devise a robust cell culture system, derived from either mutant brain or mutant iPS cells, to screen for new drug candidates. I would test any drug found to be effective to see if it could correct the behavioral abnormalities in the mutant mice, which would provide strong evidence that the defects identified in vitro are responsible for the behavioral defects. Now, finally, I would be ready to make iPS cells from ASD individuals carrying the same or a similar mutation. The results from the mouse experiments would inform these studies on human cells by suggesting the types of neural cells (neurons, glia, or both), synapses, and circuits I would need to produce, as well as how to produce them. As in the mouse experiments, I would analyze the cells in culture and after transplantation into fetal mouse brain. If I succeeded in reproducing the defects demonstrated earlier using cells derived from mutant mouse iPS cells, I would test the drugs that corrected the mouse cell defects to see if they also corrected the defects found in the human cells; if not, I would repeat the drug screen on the human cells. Any drugs found to be effective in vitro could serve as starting material for developing drugs to test in the mutant ASD individuals. If this strategy worked, it would not only be great news for the ASD individuals, it would also provide strong evidence that the identified neural defects are an important contributor to the ASD behavioral phenotype. (Note that this strategy does not entail the transplantation into humans of either iPS cells or cells derived from iPS cells, and it therefore avoids any safety concerns about the expression of transgenes or the use of pluripotent stem cells.)
Of course, long-term strategies, such as the one outlined here, rarely work out as planned. It is likely that unexpected results would suggest alternative interpretations, and new technologies would allow better experimental routes forward; brain imaging studies in mutant mice and humans, for example, might help to identify the relevant brain regions. An important concern is that differences between the mouse brain and human brain might invalidate the mouse models, which could doom the strategy. Moreover, defects in synaptic connections may not be as important as I suspect they are in at least some of the major neuropsychiatric disorders, and it may be very difficult to distinguish primary abnormalities from those that are secondary and compensatory; this strategy, however, may help to resolve these important issues.
As DNA sequencing becomes faster and cheaper, new large-effect mutations will increasingly be discovered in the neuropsychiatric disorders, providing new starting points for the strategy. On the other hand, there is no reason to wait for new genes, as there are already enough to get started, and some laboratories are well along this pathway in analyzing these genes in mouse models (for example, Fyffe et al., 2008) . There is little doubt that human iPS cells will prove to be invaluable in the search for the molecular and cellular bases of these disorders, but I suspect that, in most cases, a great deal of hard work on animal models and mouse iPS cells will first be necessary to guide the human studies.
The combination of human genetics, animal models, and iPS cells promises to revolutionize our understanding of the major neuropsychiatric disorders, as it already has done for many neurodegenerative diseases. The payoff here could be greater than it has been so far for the neurodegenerative diseases, both for the development of new effective therapies and for understanding the workings of the normal human brain, which is arguably the biggest challenge for biologists today. I could not resist being part of such a worthy adventure.
